Publications
Title
Info
2018
-
Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models.Kuipers, A., Moll, G.N., Wagner, E., Franklin, R. Peptides
2017
-
Phage display and selection of lanthipeptides on the carboxy-terminus of the gene-3 minor coat protein.Urban J.U., Moosmeier, M.A., Aumüller, T., Thein, M., Bosma, T., Rink, R., Groth, K., Zulley, M., Siegers, K., Tissot, K., Moll, G.N., Prassler, J.Nature Comm. 2017 Nov 15;8(1):1500
-
Semi-microbiological synthesis of an active lysinoalanine-bridged analog of glucagon-like-peptide-1.Kuipers, A., de Vries, L., de Vries, M.P., Rink, R., Bosma, T., Moll, G.N. Peptides 91, 33-39.
-
Mutagenesis of nisin's leader peptide proline strongly modulates export of precursor nisin.Plat, A., Kuipers, A., Crabb, J., Rink, R., Moll, G.N. Antonie Van Leeuwenhoek 110, 321-330.
-
Mechanistic aspects of lanthipeptide leaders.Plat, A., Kuipers, A., Rink, R., Moll, G.N. Curr. Protein Pept. Sci. 14, 85-96.
2015
-
GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.Carlucci, G., Kuipers, A., Ananias, H.J., de Paula Faria, D., Dierckx, R.A., Helfrich, W., Rink, R., Moll, G.N., de Jong IJ, Elsinga PH. Peptides 67, 45-54.
2012
-
The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction.Durik, M., van Veghel, R., Kuipers, A., Rink, R, Haas, Jimoh Akanbi, M., Moll, G., Danser, A.H., Roks, A.J. Int J Hypertens 2012, 536426.
-
Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury.Wagenaar, G.T., Laghmani, E.H., Fidder, M., Sengers, R.M., de Visser, Y.P., de Vries, L., Rink, R., Roks, A,J., Folkerts, G., Walther, F.J.
2011
-
Bacterial display and screening of posttranslationally thioether-stabilized peptides.Bosma, T., Kuipers, A., Bulten, E., de Vries, L., Rink, R., Moll, G.N. Appl. Environ. Microbiol. 77, 6794-801.
2010
-
To protect peptide pharmaceuticals against peptidases.Rink, R., Arkema-Meter, A., Baudoin, I., Post, E., Kuipers, A., Nelemans, S.A., Haas-Jimoh-Akanbi, M., Moll, G.N. Pharmacol. Toxicol. Methods. 61, 210–218
2009
-
Angiotensin-(1-7) with thioether-bridge: an ACE-resistant, potent Ang-(1-7) analogueKluskens, L.D., Nelemans, S.A., Rink, R., de Vries, L., Meter-Arkema, A., Wang, Y., Walther, T., Kuipers, A., Moll, G. N., and Haas, M. J. Pharmacol. Exper. Ther. 328, 849-854
-
A biological stabilization technology for peptide drugs: enzymatic introduction of thioether-bridges.Moll, G.N. Kuipers, A., de Vries, L., Bosma, T., Rink, R. Drug Discov Today: Technol. doi:10.1016/j.ddtec.2009.03.
-
Translocation of a thioether-bridged azurin peptide fragment via the sec pathway in Lactococcus lactisKuipers, A., Rink, R., Moll, G.N. Appl. Environ. Microbiol. 75, 3800-3802
-
Mechanistic dissection of the enzyme complexes involved in the biosynthesis of nisin and lacticin 3147.Kuipers, A., Meijer-Wierenga, J., Rink, R., Kluskens, L.D., and Moll, G.N. (2008), Appl. Environ. Microbiol. 74, 6591-6597